PIK3CA and breast carcinoma: Approved agents like alpelisib, combined with fulvestrant, prolong progression-free survival (median 11 vs. 5.7 months) in PIK3CA-mutant breast cancer, while idelalisib–rituximab combinations achieve 83% overall response rates in relapsed CLL.